Neurocrine Biosciences
NBIX
#1366
Rank
ยฃ11.63 B
Marketcap
ยฃ116.73
Share price
0.84%
Change (1 day)
17.82%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Revenue for Neurocrine Biosciences (NBIX)

Revenue in 2025 (TTM): ยฃ2.03 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current revenue (TTM ) is ยฃ2.01 Billion. In 2024 the company made a revenue of ยฃ1.87 Billion an increase over the revenue in the year 2023 that were of ยฃ1.48 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Neurocrine Biosciences from 1996 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) ยฃ2.03 B8.44%
2024 ยฃ1.87 B26.71%
2023 ยฃ1.48 B20.37%
2022 ยฃ1.23 B46.54%
2021 ยฃ0.83 B9.44%
2020 ยฃ0.76 B27.69%
2019 ยฃ0.60 B69.05%
2018 ยฃ0.35 B197.26%
2017 ยฃ0.11 B883.75%
2016 ยฃ12.15 M-8.87%
2015 ยฃ13.34 M
2014 N/A-100%
2013 ยฃ1.76 M-94.62%
2012 ยฃ32.87 M-33.99%
2011 ยฃ49.8 M129.5%
2010 ยฃ21.7 M1089.22%
2009 ยฃ1.82 M-32.72%
2008 ยฃ2.71 M340.2%
2007 ยฃ0.61 M-96.92%
2006 ยฃ20.03 M-72.12%
2005 ยฃ71.84 M61.93%
2004 ยฃ44.36 M-42.94%
2003 ยฃ77.74 M590.84%
2002 ยฃ11.25 M-60.43%
2001 ยฃ28.44 M191.02%
2000 ยฃ9.77 M-6.05%
1999 ยฃ10.4 M8.12%
1998 ยฃ9.62 M-39.44%
1997 ยฃ15.88 M41.7%
1996 ยฃ11.21 M

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Repligen
RGEN
ยฃ0.53 B-73.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
ยฃ1.76 B-12.41%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
ยฃ44.60 B 2,114.93%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
ยฃ44.77 B 2,123.28%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
ยฃ47.13 B 2,240.40%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
ยฃ0.62 B-69.18%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
ยฃ0.06 M-100.00%๐Ÿ‡บ๐Ÿ‡ธ USA